The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 25, 2012

Filed:

May. 18, 2006
Applicants:

Sharon Lea Aukerman, Mosaga, CA (US);

Bahija Jallal, Emeryville, CA (US);

Mohammad Luqman, Danville, CA (US);

Inventors:

Sharon Lea Aukerman, Mosaga, CA (US);

Bahija Jallal, Emeryville, CA (US);

Mohammad Luqman, Danville, CA (US);

Assignees:

Novartis AG, Basel, CH;

Xoma Technology Ltd., Berkeley, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C12Q 1/00 (2006.01); C12Q 1/68 (2006.01); G01N 33/53 (2006.01);
U.S. Cl.
CPC ...
Abstract

Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.


Find Patent Forward Citations

Loading…